60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) and Ascend Wellness (OTCMKTS:AAWH – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Institutional and Insider Ownership
8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Ascend Wellness shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 21.9% of Ascend Wellness shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
60 Degrees Pharmaceuticals has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Ascend Wellness has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 60 Degrees Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
| Ascend Wellness | 0 | 1 | 0 | 0 | 2.00 |
60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, suggesting a potential upside of 1,373.40%. Given 60 Degrees Pharmaceuticals’ higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Ascend Wellness.
Profitability
This table compares 60 Degrees Pharmaceuticals and Ascend Wellness’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 60 Degrees Pharmaceuticals | -650.21% | N/A | -136.81% |
| Ascend Wellness | -23.31% | N/A | -10.85% |
Earnings & Valuation
This table compares 60 Degrees Pharmaceuticals and Ascend Wellness”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 60 Degrees Pharmaceuticals | $1.11 million | 2.98 | -$7.36 million | ($4.82) | -0.20 |
| Ascend Wellness | $500.58 million | 0.16 | -$118.19 million | ($0.57) | -0.70 |
60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Ascend Wellness. Ascend Wellness is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
About Ascend Wellness
Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
